ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Clinical Validation of the Brain Model Published Online in the Journal NeuroImage ClearPoint Maestro Brain Model ClearPoint Maestro Brain Model ClearPoint Neuro Maestro Brain Model Comparative Reproducibility Error Results Reproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right). Bars represent range of measured relative volume difference. SOLANA BEACH, Calif., Feb. 21, 2024 (GLOBE NE
Clinical Validation of the Brain Model Published Online in the Journal NeuroImage ClearPoint Maestro Brain Model ClearPoint Maestro Brain Model ClearPoint

ClearPoint Neuro, Inc. on LinkedIn: Doctors test experimental treatment to combat seizures in epilepsy patients

ClearPoint Neuro, Inc. on LinkedIn: #neurosurgeons #clearpoint #marketing #patienteducation #employeehighlight…

ClearPoint Neuro, Inc. on LinkedIn: #clpt #aans2023 #nsgy #deepbrainstimulation #litt #neurooncology

ClearPoint Neuro, Inc. on LinkedIn: CNS Therapeutics Xchange

SNN

ClearPointNeuro (@ClearPointNeuro) / X

ClearPoint Neuro, Inc.

Vysioneer Receives FDA Clearance on First-Ever Tumor Auto-Contouring Solution for Radiation Therapy

SNN

SNN

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System

SNN

CLPT - ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock